CTNNB1 and colorectal cancer: Additional studies with these compounds revealed that they suppressed the expression of Wnt/β-catenin signaling targets axin2, cyclin D1 and survivin in both colorectal cancer HCT116 cells (harboring a CTNNB1 mutation) and SW480 cells (harboring an APC mutation) (Figure 1B), and displayed potent anticancer activities with IC50 values between 4.9 and 17.4 μM for HCT116, SW480 and SW620 cells (Table 1).